Collectively, these findings demonstrate that USP5 depletion sensitizes CRC cells to ferroptosis and suppresses tumor progression in both patient-derived organoid and in vivo xenograft models, highlighting the USP5/YBX3-ferroptosis axis as a potential therapeutic target in CRC. The gene discussed is USP5; the disease is neoplasm.